Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856773 · ClinicalTrials.gov registry record · Phase 3
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
A Phase 3 study of Breast Cancer, sponsored by Proton Collaborative Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 7
- Study locations
NCT05856773: Recruiting Phase 3 study of Breast Cancer, sponsored by Proton Collaborative Group.
NCT05856773 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Proton Collaborative Group. The registered enrollment target is 276 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05856773, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Proton Collaborative Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.
Conditions Studied
Interventions
- RADIATION Proton Therapy
Study Locations (7)
Florida
- University of Florida Proton Therapy Institute - Jacksonville
- Miami Cancer Institute - Miami
Arizona
- Mayo Clinic - Scottsdale
California
- California Protons Cancer Therapy Center - San Diego
Georgia
- Emory Proton Therapy Center - Atlanta
New York
- New York Proton Center - New York
Virginia
- Inova Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2024-03-21 |
| Est. Completion | 2041-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05856773
The ClinicalTrials.gov registry entry for NCT05856773 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Proton Collaborative Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Proton Therapy is the first listed.
NCT05856773 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05856773 about?
NCT05856773 is a clinical study titled "Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy". The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall...
What is the current status of trial NCT05856773?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2024-03-21. Estimated completion is 2041-02.
What conditions does trial NCT05856773 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05856773?
The interventions under investigation include: Proton Therapy (RADIATION).
Who is sponsoring clinical trial NCT05856773?
This trial is sponsored by Proton Collaborative Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05856773 being conducted?
This trial has 7 study locations across Arizona, California, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.